Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

IRL790 is a novel compound with psychomotor stabilizing properties primarily targeting the dopamine D3 receptor. IRL790 is developed as an experimental treatment for levodopa-induced dyskinesia (LID), impulse control disorder, and psychosis in Parkinson’s disease (PD). The primary objective was to i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:NPJ Parkinsons Dis
Hauptverfasser: Svenningsson, Per, Johansson, Anders, Nyholm, Dag, Tsitsi, Panagiota, Hansson, Fredrik, Sonesson, Clas, Tedroff, Joakim
Format: Artigo
Sprache:Inglês
Veröffentlicht: Nature Publishing Group UK 2018
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6283839/
https://ncbi.nlm.nih.gov/pubmed/30534585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41531-018-0071-3
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge